Meiji Yasuda America Inc Acquires Shares of 9,812 Amgen Inc. $AMGN

Posted by Brian Himes on Jun 12th, 2026

Meiji Yasuda America Inc acquired a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,812 shares of the medical research company’s stock, valued at approximately $3,212,000.

A number of other hedge funds also recently bought and sold shares of the business. Buckley Wealth Management LLC raised its holdings in Amgen by 0.3% in the 4th quarter. Buckley Wealth Management LLC now owns 33,235 shares of the medical research company’s stock valued at $10,878,000 after acquiring an additional 87 shares during the last quarter. Sumitomo Mitsui Financial Group Inc. raised its holdings in Amgen by 3.1% in the 4th quarter. Sumitomo Mitsui Financial Group Inc. now owns 78,123 shares of the medical research company’s stock valued at $25,570,000 after acquiring an additional 2,344 shares during the last quarter. First Financial Bankshares Inc raised its holdings in Amgen by 0.9% in the 4th quarter. First Financial Bankshares Inc now owns 222,322 shares of the medical research company’s stock valued at $72,768,000 after acquiring an additional 1,900 shares during the last quarter. Xponance LLC raised its holdings in Amgen by 5.3% in the 4th quarter. Xponance LLC now owns 125,333 shares of the medical research company’s stock valued at $41,023,000 after acquiring an additional 6,318 shares during the last quarter. Finally, Canopy Partners LLC raised its holdings in Amgen by 4.2% in the 4th quarter. Canopy Partners LLC now owns 4,566 shares of the medical research company’s stock valued at $1,494,000 after acquiring an additional 183 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. UBS Group boosted their target price on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Daiwa Securities Group decreased their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Finally, Argus decreased their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $354.12.

Check Out Our Latest Report on Amgen

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $354.06 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a market capitalization of $191.09 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 3.39 and a beta of 0.42. The company’s 50-day moving average is $340.94 and its two-hundred day moving average is $345.65. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.